SBIR-STTR Award

Development of a GABA Enzyme for Biosensor Applications
Award last edited on: 1/11/2018

Sponsored Program
SBIR
Awarding Agency
NIH : NIMHD
Total Award Amount
$1,365,122
Award Phase
2
Solicitation Topic Code
101
Principal Investigator
David A Johnson

Company Information

Pinnacle Technology Inc

2721 Oregon Street
Lawrence, KS 66046
   (785) 832-8866
   sales@pinnaclet.com
   www.pinnaclet.com
Location: Single
Congr. District: 01
County: Douglas

Phase I

Contract Number: 1R43MH109188-01
Start Date: 6/1/2016    Completed: 5/31/2017
Phase I year
2016
Phase I Amount
$153,963
As the most important inhibitory neurotransmitter in the brain, a detailed understanding of the implications of gamma-aminobutyric acid (GABA) release remains elusive. The measurement of GABA concentrations is a difficult process. Microdialysis is the current standard for GABA sampling in the brains of freely moving animals, but suffers from low temporal resolution and the need for labor intensive analysis methods. By contrast, the direct sensing of GABA, by modalities including biosensors, provides second-by-second temporal resolution, without the need for additional post-analysis. However, biosensors and other monitoring devices, require an enzyme to process the analyte of interest. The state-of-the-art for the enzymatic conversion of GABA into a transducible signal is the sequential activity of three separate enzymes or antibodies entrapped within nanoparticles. For CNS and systemic GABA sensing applications, a single GABA oxidase enzyme is necessary. No such oxidase enzyme for GABA is currently available. To develop this enzyme, Pinnacle will team with an interdisciplinary group of two leading scientists at the University of Kansas. Professor Mark Richter, is an expert in protein engineering and protein folding, and Dr. Philip Gao, is the Director of the Protein Production Core Facility. This team has already cloned, expressed purified and characterized an oxidase enzyme (wt-pUUB-Ox) with some GABA activity. During Phase I, we will use this oxidase enzyme as a starting scaffold to evolve a true GABA oxidase enzyme. At the end of Phase 1, we will have an oxidase enzyme with a 10x - 50x improvement in GABA activity relative to wt-pUUB-Ox, and a clear path for Phase II to oxidase activity and stability suitable for the specific measurement of physiologically relevant GABA concentrations. This evolved GABA oxidase enzyme will, in a single reaction step, oxidize GABA to produce hydrogen peroxide as a byproduct. The GABA oxidase enzyme can be used as the basis for new monitoring paradigms that would otherwise be impossible. By the end of Phase II, two commercially available products will be available. First, a GABA biosensor for real-time measurement of physiologically relevant levels of GABA in the brain for preclinical models and second, a GABA oxidase enzyme for use in a variety of diagnostic and point-of-care devices.

Public Health Relevance Statement:


Public Health Relevance:
GABA is the major inhibitory neurotransmitter in the brain and plays an important role in disorders ranging from newborn seizures to anxiety, Alzheimer's, Huntington's, Parkinson's diseases and a wide variety of cancers. The efficacy of disease models in research is well established for the development of treatments. The quality of life, and economic, costs of these, and other illnesses in which GABA plays a role, are staggering. These disorders disrupt millions of lives, and America spends billions of dollars each year in hospital visits, nursing home stays, and lost productivity.

NIH Spending Category:
Bioengineering; Biotechnology; Mental Health; Neurosciences

Project Terms:
Address; Alzheimer's Disease; Americas; analytical method; Animal Model; Animals; Antibodies; Anxiety; base; Biosensing Techniques; Biosensor; Brain; Characteristics; commercialization; Core Facility; design; Detection; Development; Devices; Diagnostic; Directed Molecular Evolution; Disease; Disease model; drug development; drug discovery; economic cost; Electronics; Elements; Engineering; Enzymes; experience; gamma-Aminobutyric Acid; Goals; Hospitals; Hour; Human; Huntington Disease; Hydrogen Peroxide; hypnotic; Immobilization; improved; in vivo; innovation; interest; Kansas; large scale production; Malignant Neoplasms; Measurement; Methods; Microdialysis; Modality; Monitor; monitoring device; nanoparticle; Neuraxis; neurochemistry; neuronal excitability; Neurotransmitters; Newborn Infant; novel; nursing home length of stay; Outcome; Oxidases; Parkinson Disease; Pharmacologic Substance; Phase; Physiological; Play; point of care; point-of-care diagnostics; pre-clinical; Pre-Clinical Model; Procedures; Process; Production; Productivity; professor; Protein Engineering; protein folding; Proteins; Protocols documentation; public health relevance; Putrescine; Quality of life; Reaction; Research; Research Design; research study; Role; Sales; Sampling; scaffold; Scientist; Seizures; Signal Transduction; Skeleton; Small Business Innovation Research Grant; System; Techniques; Technology; temporal measurement; therapy development; Time; Universities; Visiting Nurse; Work

Phase II

Contract Number: 2R44MH109188-02
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
2017
(last award dollars: 2018)
Phase II Amount
$1,211,159

As the most important inhibitory neurotransmitter in the brain, a detailed understanding of the implications of gamma-aminobutyric acid (GABA) release remains elusive. The measurement of GABA concentrations is a difficult process. Microdialysis is the current standard for GABA sampling in the brains of freely moving animals, but suffers from low temporal resolution and the need for labor intensive analysis methods. By contrast, the direct sensing of GABA, by modalities including biosensors, would provide second-by-second temporal resolution, without the need for additional post- analysis. However, biosensors and other monitoring devices, require an enzyme to process the analyte of interest. The state-of-the-art for the enzymatic conversion of GABA into a transducible signal is the sequential activity of multiple enzymes or antibodies entrapped within nanoparticles. For brain and systemic GABA sensing applications, a single GABA oxidase enzyme is necessary. No such oxidase enzyme for GABA is currently available. This proposal addresses this problem by designing a single GABA-specific oxidase enzyme for use as the biorecognition element that is suitable for fabrication of a GABA biosensor. During Phase I we identified, isolated, purified, cloned, crystallized and modeled the active-site structure of ?-N- Methylaminobutyrate oxidase (MGOX). We set up a directed evolution system (KJ109) in which there will only be growth if GABA is available as a nitrogen source, and we demonstrated that the preliminary MGOX enzyme can be used on a biosensor to detect GABA. For Phase II of this project, there are two major problems that must be solved: (1) Modification of MGOX to increase its kcat at physiological pH (~pH 7.4); and (2) Modification of MGOX to increase sensitivity to detect physiologically relevant GABA concentrations. Pinnacle will team with an interdisciplinary group of two leading scientists at the University of Kansas. Professor Mark Richter, is an expert in protein engineering and protein folding, and Dr. Philip Gao, is the Director of the Protein Production Core Facility. By the end of Phase II, two commercially available products will be available. First, a GABA biosensor for real-time measurement of physiologically relevant levels of GABA in the brain for preclinical animal models and second, a GABA oxidase enzyme for use in a variety of diagnostic and point-of-care devices.

Public Health Relevance Statement:
Narrative GABA is the major inhibitory neurotransmitter in the brain and plays an important role in disorders ranging from seizures to anxiety, Alzheimer’s, Huntington’s, Parkinson’s diseases and a wide variety of cancers. The efficacy of disease models in research is well established for the development of treatments. The quality of life, and economic, costs of these, and other illnesses in which GABA plays a role, are staggering. These disorders disrupt millions of lives, and America spends billions of dollars each year in hospital visits, nursing home stays, and lost productivity.

Project Terms:
Active Sites; Address; Affinity; Alzheimer's Disease; Americas; Amino Acids; Animal Model; Animals; Antibodies; Anxiety; ascorbate; Biosensor; Brain; brain circuitry; Cells; Collection; Complex; Core Facility; Crystallization; design; Development; Devices; Diagnostic; Directed Molecular Evolution; Disease; Disease model; DNA; DNA-Directed RNA Polymerase; economic cost; Electrodes; Electronics; Elements; Ensure; Environmental Risk Factor; enzyme immobilization; enzyme structure; Enzymes; Exhibits; experience; gamma-Aminobutyric Acid; Genes; Growth; Hospitals; Huntington Disease; Immobilized Enzymes; improved; improved functioning; in vivo; Individual; interest; Kansas; Life; Malignant Neoplasms; Measurable; Measurement; meetings; Methods; Microdialysis; Modality; Modeling; Modification; Monitor; monitoring device; Mus; mutant; Mutation; nanoparticle; Neuraxis; Neurotransmitters; Nitrogen; novel; nursing home length of stay; Oxidases; Parkinson Disease; Phase; Physiological; Play; point of care; pre-clinical; Process; Production; Productivity; professor; Progress Reports; Property; Protein Engineering; protein folding; Proteins; Quality of life; Rattus; Reaction Time; Research; Resolution; Role; Sales; Sampling; Scientist; Seizures; Signal Transduction; Source; Structure; Substrate Specificity; System; Technology; Temperature; temporal measurement; therapy development; Time; tool; Universities; Visiting Nurse; Work